Analysis
PublicLEIDOS BIOMEDICAL RESEARCH, INC. holds $2.3B across 187 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75N91019D00024. PoP ended Nov 29, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.
Contract facts
FederalNIAID DMID BIG EFFECT TRIAL (BET) - INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED A MULTICENTER PLATFORM EVALUATING PUTATIVE THERAPEUTICS FOR THE TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS (SHORT TITLE,
Recompete timing
PublicCurrent PoP ended Nov 29, 2024 (625 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Watch this contract — one email →Incumbent footprint
Public recordLEIDOS BIOMEDICAL RESEARCH, INC. — $2.3B obligated across 187 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Track this contract
Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open LEIDOS BIOMEDICAL RESEARCH, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Frequently asked questions
What is contract 75N91020F00011?
75N91020F00011 (NIAID DMID BIG EFFECT TRIAL (BET) - INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL…) is a Department of Health and Human Services (HHS) award with an estimated value of $62.1M, currently held by LEIDOS BIOMEDICAL RESEARCH, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.
Who is the incumbent on 75N91020F00011?
LEIDOS BIOMEDICAL RESEARCH, INC. is the incumbent with $2.3B across 187 related awards in SCOUT’s public footprint. The current period of performance ends Nov 29, 2024.
When does 75N91020F00011 come up for recompete?
SCOUT tracks a period-of-performance end of Nov 29, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →